Iloperidone

證據等級: L5

預測適應症: 10 個

Iloperidone: From Schizophrenia to Manic Bipolar Affective Disorder

One-Sentence Summary

Iloperidone (Fanapt®) is a second-generation atypical antipsychotic, originally approved by the FDA in 2009 for the treatment of schizophrenia in adults. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder — a prediction strongly supported by real-world evidence, with 1 registered clinical trial and 19 publications, including a pivotal Phase 3 RCT that led to FDA approval for bipolar I disorder in 2024. Although TxGNN ranks this indication 10th by graph score (99.977%), it represents the only clinically actionable finding in this evidence pack — the top 9 TxGNN predictions are all L5 (model-only) with Hold recommendations.

Quick Overview

Item	Content
Original Indication	Schizophrenia (FDA-approved 2009)
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.977%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Iloperidone is a benzisoxazole atypical antipsychotic that acts as a dual D2 dopamine receptor and 5-HT2A serotonin receptor antagonist. This mechanism is the pharmacological backbone of most approved antimanic agents in the second-generation antipsychotic class — risperidone, olanzapine, quetiapine, and asenapine all share this core profile and carry regulatory approval for bipolar I disorder. The 5-HT2A antagonism modulates downstream dopaminergic hyperactivity in limbic circuits, which is the primary neurobiological driver of manic episodes.

Schizophrenia and manic bipolar affective disorder share overlapping neurobiology: both involve pathological hyperdopaminergic states in mesolimbic pathways, and both respond to D2/5-HT2A blockade. This mechanistic overlap is precisely why most atypical antipsychotics approved for schizophrenia eventually gain bipolar indications — the therapeutic target is shared across diagnostic boundaries. Iloperidone’s receptor binding profile is particularly well-suited: its relatively lower D2 binding affinity compared to older agents may reduce extrapyramidal side effects while the 5-HT2A antagonism provides mood-stabilising properties.

Crucially, this is not merely a theoretical prediction. A Phase 3, double-blind, placebo-controlled trial (PMID 38236020, published 2024 in Journal of Clinical Psychiatry) confirmed iloperidone’s efficacy in acute bipolar mania using the Young Mania Rating Scale as the primary endpoint. The FDA approved this new indication in 2024, making the TxGNN model’s prediction retrospectively validated at the highest evidence tier.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02413918	Phase 4	Completed	41	Open-label study of iloperidone as adjunctive treatment to lithium, divalproex, or lamotrigine in bipolar mixed states; assessed acute and long-term bimodal efficacy and predictors of treatment response

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38236020	2024	RCT	J Clin Psychiatry	Phase 3, double-blind, placebo-controlled trial; iloperidone up to 24 mg/day for 4 weeks significantly reduced YMRS scores vs. placebo in adults with bipolar mania — the pivotal trial supporting FDA approval
39800949	2025	Review/Meta-analysis	Ann Pharmacother	Comprehensive review of iloperidone’s efficacy for mania in bipolar I disorder and safety profile (QTc prolongation, orthostatic hypotension, metabolic effects)
39008105	2024	Drug Update	Med Lett Drugs Ther	Formal drug update commentary on iloperidone’s new FDA-approved indication for bipolar disorder
28817490	2017	Open-label Trial	J Clin Psychopharmacol	Open trial of iloperidone in bipolar mixed episodes; assessed depression response alongside manic symptoms over short- and long-term observation
30187288	2018	Systematic Review	Drugs Aging	Pharmacological and clinical review of newer atypical antipsychotics including iloperidone for bipolar disorder in older adults
22849428	2012	Narrative Review	Expert Opin Pharmacother	Primer on iloperidone, asenapine, and lurasidone covering schizophrenia and bipolar indications; describes iloperidone’s serotonin/dopamine antagonism as the mechanistic basis for mood stabilisation
41826282	2026	Pharmacogenomics Study	Pharmacogenomics J	Analysis of SLC2A9 variant rs7442295 and uric acid levels in patients from the Phase 3 bipolar mania trial; iloperidone associated with increased uric acid from baseline
22900950	2012	Comparative Safety Study	CNS Drugs	Systematic review and meta-analysis comparing metabolic adverse effects (weight, glucose, lipids) of iloperidone, asenapine, lurasidone, and paliperidone across schizophrenia and bipolar disorder populations
39126643	2024	Safety Review	Expert Opin Drug Saf	Updated review on QTc interval prolongation risk and Torsades de Pointes for atypical antipsychotics including iloperidone; addresses clinical surveillance recommendations
31065941	2019	Systematic Review/Meta-analysis	CNS Drugs	Meta-analysis on medication-induced akathisia with newer antipsychotics including iloperidone across severe mental illness indications

India Market Information

Iloperidone is currently not marketed in India. No drug registrations have been filed or approved with the Central Drugs Standard Control Organisation (CDSCO). The drug is approved and marketed in the United States (as Fanapt® by Vanda Pharmaceuticals) for schizophrenia (since 2009) and bipolar I disorder manic/mixed episodes (since 2024), but has no regulatory footprint in the Indian market at the time of this report.

Safety Considerations

Drug Interactions (239 interactions identified; selected Major-level interactions):

Interacting Drug	Severity	Clinical Concern
Clarithromycin	Major	CYP3A4 inhibition increases iloperidone plasma levels; risk of QTc prolongation and Torsades de Pointes
Bupropion	Major	CYP2D6 inhibition by bupropion elevates iloperidone concentrations; increased risk of adverse CNS and cardiac effects
Morphine	Major	Additive CNS depression; respiratory depression risk in combination

Moderate interactions identified for 236 additional agents, including antidiabetic drugs (metformin, pioglitazone, canagliflozin, acarbose), anticholinergics (atropine, hyoscyamine, glycopyrronium), and catecholamines (epinephrine). The anticholinergic and antidiabetic interactions are clinically relevant given that metabolic syndrome and anticholinergic burden are common considerations in psychiatric populations.

QTc Prolongation Risk: Multiple publications in this evidence pack (PMID 39126643, PMID 22900950) confirm that iloperidone carries a clinically meaningful QTc-prolonging effect. Baseline and on-treatment ECG monitoring is standard of care. Avoid combination with other QTc-prolonging agents.

Orthostatic Hypotension: Noted as a class-specific concern for iloperidone in the clinical review literature (PMID 39800949). Dose titration should be gradual to minimise haemodynamic effects.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Iloperidone’s efficacy for manic bipolar affective disorder is supported by the highest level of clinical evidence — a Phase 3 double-blind placebo-controlled RCT published in 2024 resulted in FDA approval for this exact indication. The mechanistic basis (D2/5-HT2A antagonism) is identical to that of multiple drugs already approved for bipolar I disorder. This is not speculative repurposing; it is a confirmed new indication that has not yet reached the Indian market.

To proceed, the following is needed:

CDSCO registration pathway: Iloperidone has no existing India registration. A New Drug Application (NDA) or abbreviated dossier leveraging FDA approval as a reference would be required.
Local package insert and safety data: Formal TFDA/CDSCO-format warnings, contraindications, and prescribing information need to be compiled — currently flagged as a data gap (DG001).
QTc monitoring protocol: Given the Major DDI risk with CYP3A4 inhibitors (clarithromycin) and known QTc-prolonging properties, a mandatory ECG monitoring plan should accompany any clinical deployment.
Pharmacogenomic consideration: Iloperidone is metabolised primarily by CYP2D6 and CYP3A4. CYP2D6 poor metabolisers have significantly higher drug exposure. Genotype-guided dosing guidance or dose adjustment guidelines for the Indian population should be assessed.
Metabolic monitoring plan: Given interactions with antidiabetic drugs and known metabolic effects, baseline and periodic monitoring of fasting glucose, HbA1c, lipid panel, and body weight is recommended.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.